157-48-2

Basic information

• Product Name: 1-OXASPIRO[2.3]HEXANE
• Synonyms: 1-OXASPIRO[2.3]HEXANE
• CAS NO: 157-48-2
• Molecular Formula: C₅H₈O
• Molecular Weight: 84.12
• Mol File: 157-48-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 89-92 °C(Press: 754 Torr)
• Appearance: /
• Density: 0.9284 g/cm3(Temp: 0 °C)
• CAS DataBase Reference: 1-OXASPIRO[2.3]HEXANE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-OXASPIRO[2.3]HEXANE(157-48-2)
• EPA Substance Registry System: 1-OXASPIRO[2.3]HEXANE(157-48-2)

Safety Data

• Hazardous Substances Data: 157-48-2(Hazardous Substances Data)

Usage

Uses

1-?Oxaspiro[2.3]?hexane is used as a reactant in the preparation of spiro γ-lactones via aluminum enolate-spiro epoxide openings.

Upstream product

• 1191-95-3 cyclobutanone 
• 1774-47-6 trimethylsulfoxonium iodide 
• 1120-56-5 methylidenecyclobutane 
• 98070-78-1 1-chloromethyl-cyclobutanol 

Downstream Products

• 1120-56-5 methylidenecyclobutane 

Relevant articles and documents

NON-FUSED TRICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

PHARMACOLOGICALLY ACTIVE COMPOUNDS

The present invention relates to compounds of formula (II) wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 – also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to thiazolidinylidene containing compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, compositions comprising su